Disease of the Year 2019: Ocular Toxoplasmosis in HIV-infected Patients

References

• Moraes HV. Ocular manifestations of HIV/AIDS. Curr Opin Ophthalmol. 2002;13(6):397–403. doi:10.1097/00055735-200212000-00010.
   PubMedGoogle Scholar
• Biswas J, Madhavan HN, George AE, Kumarasamy N, Solomon S. Ocular lesions associated with HIV infection in India: A series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol. 2000;129(1):9–15. doi:10.1016/S0002-9394(99)00415-8.
   PubMed Web of Science ®Google Scholar
• Rodrigues ML, Rodrigues MDLV, Figueiredo JFDC, Freitas JAHD. Ocular problems in brazilian patients with AIDS before and in highly active antiretroviral therapy (HAART) era. Brazilian J Infect Dis. 2007;11(2):199–202. doi:10.1590/s1413-86702007000200005.
   PubMed Web of Science ®Google Scholar
• Hodge WG, Seiff SR, Margolis TP. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology. 1998;105(5):895–900. doi:10.1016/S0161-6420(98)95033-3.
   PubMed Web of Science ®Google Scholar
• Maclean H, Hall AJH, McCombe MF, Sandland AM. AIDS and the eye A 10-year experience. Aust N Z J Ophthalmol. 1996;24(1):61–67. doi:10.1111/j.1442-9071.1996.tb01553.x.
   PubMedGoogle Scholar
• Wang Z, Jia R, Ge S, et al. Ocular complications of human immunodeficiency virus infection in eastern China. Am J Ophthalmol. 2012;153(2):363–370.doi:10.1016/j.ajo.2011.07.018.
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Mohraz M, Rasoulinejad M, et al. Retinitis due to opportunistic infections in Iranian HIV infected patients. Acta Med Iran. 2013;51(10):711–714.
   PubMedGoogle Scholar
• Emina MO, Odjimogho SE. Ocular problems in HIV and AIDS patients in Nigeria. Optom Vis Sci. 2010;87(12):979–984. doi:10.1097/OPX.0b013e3181fef198.
   PubMed Web of Science ®Google Scholar
• Vrabec TR. Posterior segment manifestations of HIV/AIDS. Surv Ophthalmol. 2004;49(2):131–157. doi:10.1016/j.survophthal.2003.12.008.
   PubMed Web of Science ®Google Scholar
• Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clin Exp Ophthalmol. 2013;41(1):95–108. doi:10.1111/ceo.2013.41.issue-1.
   PubMed Web of Science ®Google Scholar
• Holland GN. Ocular toxoplasmosis: a global reassessment: part II: disease manifestations and management. Am J Ophthalmol. 2004;137:1–17.
   PubMed Web of Science ®Google Scholar
• Chiotan C, Radu L, Serban R, Cornacel C, Cioboata M, Anghelie A. Posterior segment ocular manifestations of HIV/AIDS patients. J Med Life. 2014;7:399–402.
   PubMedGoogle Scholar
• Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol. 2003;74(2):179–185. doi:10.1189/jlb.1102574.
   PubMed Web of Science ®Google Scholar
• Streilein JW. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Curr Opin Immunol. 1993;5(3):428–432. doi:10.1016/0952-7915(93)90064-Y.
   PubMed Web of Science ®Google Scholar
• Norose K, Kikumura A, Luster AD, Hunter CA, Harris TH. CXCL10 is required to maintain T-cell populations and to control parasite replication during chronic ocular Toxoplasmosis. Investig Opthalmol Vis Sci. 2011;52(1):389. doi:10.1167/iovs.10-5819.
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Brezin A, Li Q, Nussenblatt RB, Chan CC. Toxoplasma gondii: acquired ocular toxoplasmosis in the murine model, protective role of TNF-α and IFN-γ. Exp Parasitol. 1994;78(2):217–229. doi:10.1006/expr.1994.1022.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Mittal KK, Fuhrman S, Sharma SD, Palestine AG. Lymphocyte proliferative responses of patients with ocular toxoplasmosis to parasite and retinal antigens. Am J Ophthalmol. 1989;107:632–641. doi:10.1016/0002-9394(89)90260-2.
   PubMed Web of Science ®Google Scholar
• Kikumura A, Ishikawa T, Norose K. Kinetic analysis of cytokines, chemokines, chemokine receptors and adhesion molecules in murine ocular toxoplasmosis. Br J Ophthalmol. 2012;96(9):1259–1267. doi:10.1136/bjophthalmol-2012-301490.
   PubMed Web of Science ®Google Scholar
• Gómez Marín JE, Pinon JMM, Bonhomme A, et al. Does human toxoplasmosis involve an imbalance in T1/T2 cytokines?. Med Hypotheses. 1997;48(2):161–169.doi:10.1016/S0306-9877(97)90283-8.
   PubMed Web of Science ®Google Scholar
• Sullivan WJ, Jeffers V. Mechanisms of toxoplasma gondii persistence and latency. FEMS Microbiol Rev. 2012;36(3):717–733. doi:10.1111/j.1574-6976.2011.00305.x.
   PubMed Web of Science ®Google Scholar
• Rodgers CA, Harris JRW. Ocular toxoplasmosis in HIV infection. Int J STD AIDS. 1996;7(5):307–309. doi:10.1258/0956462961918068.
   PubMed Web of Science ®Google Scholar
• Cristina Sarmiento M, Gómez Marín JE, Castaño Osorio JC. Evaluation of the igg anti-toxoplasma response and its avidity by western-blot in HIV-patients. Rev Cubana Med Trop. 2005;57:125–132.
   PubMedGoogle Scholar
• Hellerbrand C, Goebel FD, Disko R. High predictive value ofToxoplasma gondii IgG antibody levels in HIV-infected patients for diagnosis of cerebral toxoplasmosis. Eur J Clin Microbiol Infect Dis. 1996;15(11):869–872. doi:10.1007/BF01691219.
   PubMed Web of Science ®Google Scholar
• Gomez Marín JE, Corredor A, Murcia M, et al. Valor diagnóstico de la medición de IG G, Ig M e IG A en pacientes infectados por VIH. Infectio. 2000;4(2):4–10.
   Google Scholar
• Vidal JE, Hernández Diaz AV, de Oliveira ACP, et al. Importance of high IgG anti-toxoplasma gondii titers and PCR detection of T. gondii DNA in peripheral blood samples for the diagnosis of AIDS-related cerebral toxoplasmosis: A case-control study. Brazilian J Infect Dis. 2011;15(4):356–359.doi:10.1016/S1413-8670(11)70204-5.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009;39(8):895–901. doi:10.1016/j.ijpara.2009.02.004.
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr. Uveitis in HIV Positive Patients. Br J Ophthalmol. 2000 Mar;84(3):233–235. Review. doi:10.1136/bjo.84.3.233.
   Google Scholar
• Bekele S, Gelaw Y, Tessema F. Ocular manifestation of HIV/AIDS and correlation with CD4+ cells count among adult HIV/AIDS patients in Jimma town, Ethiopia: a cross sectional study. BMC Ophthalmol. 2013;13(1):20. doi:10.1186/1471-2415-13-20.
   PubMedGoogle Scholar
• Sendi P, Sachers F, Drechsler H, Graber P. Immune recovery vitritis in an HIV patient with isolated toxoplasmic retinochoroiditis. AIDS. 2006;20(17):2237–2238. doi:10.1097/01.aids.0000252056.53062.c8.
   PubMed Web of Science ®Google Scholar
• Otiti-Sengeri J, Meenken C, van den Horn GJ, Kempen JH. Ocular immune reconstitution inflammatory syndromes. Curr Opin HIV AIDS. 2008;3(4):432–437. doi:10.1097/COH.0b013e328302cc3d.
   PubMed Web of Science ®Google Scholar
• Ayoade F, Chandranesan ASJ. HIV-1 associated opportunistic infections, toxoplasmosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. PubMed PMID: 28722907. http://www.ncbi.nlm.nih.gov/books/NBK441877/.
   Google Scholar
• Bowen LN, Smith B, Reich D, Quezado M, Nath A. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol. 2016;12(11):662. doi:10.1038/nrneurol.2016.149.
   PubMed Web of Science ®Google Scholar
• Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al. Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophthalmol. 1992;114(2):130–135. doi:10.1016/S0002-9394(14)73975-3.
   PubMed Web of Science ®Google Scholar
• Zajdenweber M, Muccioli C, Belfort JR. Ocular involvement in AIDS patients with central nervous system toxoplasmosis: before and after HAART. Arq Bras Oftalmol. 2005;68(6):773–775. doi:10.1590/S0004-27492005000600012.
   PubMedGoogle Scholar
• Meira CS, Pereira-Chioccola VL, Vidal JE, et al. Cerebral and ocular toxoplasmosis related with IFN-γ, TNF-α, and IL-10 levels. Front Microbiol. 2014;5:1. doi:10.3389/fmicb.2014.00547.
   PubMed Web of Science ®Google Scholar
• GN H, Engstrom JRE, BJ G, et al. Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106(6):653–667. doi:10.1016/0002-9394(88)90697-6.
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Smith RE, Rao NA. Progressive ocular toxoplasmosis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115(6):742–747. doi:10.1016/S0002-9394(14)73641-4.
   PubMed Web of Science ®Google Scholar
• Pivetti-Pezzi P, Accorinti M, Tamburi S, Ciapparoni V, Abdulaziz MA. Clinical features of toxoplasmic retinochoroiditis in patients with acquired immunodeficiency syndrome. Ann Ophthalmol. 1994;26:73.
   PubMedGoogle Scholar
• Holland GN. Ocular toxoplasmosis: a global reassessment. Am J Ophthalmol. 2003;136(6):973–988. doi:10.1016/j.ajo.2003.09.040.
   PubMed Web of Science ®Google Scholar
• Smith JR, Cunningham ET. Atypical presentations of ocular toxoplasmosis. Curr Opin Ophthalmol. 2002;13(6):387–392. doi:10.1097/00055735-200212000-00008.
   PubMedGoogle Scholar
• Moraes JHV. Punctate outer retinal toxoplasmosis in an HIV-positive child. Ocul Immunol Inflamm. 1999;7(2):93–95. doi:10.1076/ocii.7.2.93.4021.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Specht CS, Allaire G, Leavitt JA. Toxoplasma gondii retinochoroiditis and optic neuritis in acquired immune deficiency syndrome: report of a case. Ophthalmology. 1990;97(10):1342–1346. doi:10.1016/S0161-6420(90)32412-0.
   PubMed Web of Science ®Google Scholar
• Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxoplasmosis. Am J Ophthalmol. 1981;92(4):497–503. doi:10.1016/0002-9394(81)90642-5.
   PubMed Web of Science ®Google Scholar
• Campos FA, de Andrade GMQ, de Pádua Santos LA, Lage BF, Assumpção MVM, Pinto JA. Incidence of congenital toxoplasmosis among infants born to HIV-coinfected mothers: case series and literature review. Brazilian J Infect Dis. 2014;18(6):609–617. doi:10.1016/j.bjid.2014.05.008.
   PubMed Web of Science ®Google Scholar
• Fernandes MA, Batista GI, Carlos JDCS, et al. Toxoplasma gondii antibody profile in HIV-1-infected and uninfected pregnant women and the impact on congenital toxoplasmosis diagnosis in Rio de Janeiro, Brazil. Brazilian J Infect Dis. 2012;16(2):170–1174. doi:10.1016/S1413-8670(12)70300-8.
   PubMed Web of Science ®Google Scholar
• Dunn D, Newell M-L, Gilbert R. Low risk of congenital toxoplasmosis in children born to women infected with human immunodeficiency virus. Pediatr Infect Dis J. 1997;16(1):84. doi:10.1097/00006454-199701000-00023.
   PubMed Web of Science ®Google Scholar
• Wang Z-D, Liu -H-H, Ma Z-X, et al. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol. 2017;8:389.
   PubMed Web of Science ®Google Scholar
• McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study. Clin Infect Dis. 2006;42(10):1383–1394. doi:10.1086/501360.
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology. 2004;111(4):716–725. doi:10.1016/j.ophtha.2003.07.004.
   PubMed Web of Science ®Google Scholar
• Villard O, Cimon B, L’Ollivier C, et al. Serological diagnosis of Toxoplasma gondii infection: recommendations from the French National Reference Center for Toxoplasmosis. Diagn Microbiol Infect Dis. 2016;84(1):22–33. doi:10.1016/j.diagmicrobio.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Colombo FA, Vidal JE, Penalva De Oliveira AC, et al. Diagnosis of cerebral toxoplasmosis in AIDS patients in Brazil: importance of molecular and immunological methods using peripheral blood samples. J Clin Microbiol. 2005;43(10):5044–5047.doi:10.1128/JCM.43.10.5044-5047.2005.
   PubMed Web of Science ®Google Scholar
• Enrique Arenas N, Ramírez N, González G, et al. Estado de la coinfección tuberculosis/virus de la inmunodeficiencia humana en el municipio de Armenia (Colombia): experiencia de 10 años. Infectio. 2012;16(3):140–147.doi:10.1016/S0123-9392(12)70003-6.
   Google Scholar
• Ozgonul C, Besirli CG. Recent developments in the diagnosis and treatment of ocular toxoplasmosis. Ophthalmic Res. 2017;57(1):1–12. doi:10.1159/000449169.
   PubMed Web of Science ®Google Scholar
• Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and sensitive detection of a pathogenic protozoan, toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol. 1989;27(8):1787–1792. doi:10.1128/JCM.27.8.1787-1792.1989.
   PubMed Web of Science ®Google Scholar
• Brézin AP, Eqwuagu CE, Silveira C, et al. Analysis of aqueous humor in ocular toxoplasmosis. N Engl J Med. 1991;324(10):699.
   PubMed Web of Science ®Google Scholar
• Robert-Gangneux F, Belaz S. Molecular diagnosis of toxoplasmosis in immunocompromised patients. Curr Opin Infect Dis. 2016;29(4):330–339. doi:10.1097/QCO.0000000000000275.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Parmley S, Liesenfeld O, Jaffe GJ, Remington JS. Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmology. 1999;106(8):1554–1563. doi:10.1016/S0161-6420(99)90453-0.
   PubMed Web of Science ®Google Scholar
• Fardeau C, Romand S, Rao NA, et al. Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am J Ophthalmol. 2002;134(2):196–203. doi:10.1016/S0002-9394(02)01500-3.
   PubMed Web of Science ®Google Scholar
• Lavinsky D, Romano A, Muccioli C, Belfort JR. Imaging in ocular toxoplasmosis. Int Ophthalmol Clin. 2012;52(4):131–143. doi:10.1097/IIO.0b013e318265fd78.
   PubMedGoogle Scholar
• Holland GN. Ocular toxoplasmosis in the immunocompromised host. Int Ophthalmol. 1989;13(6):399–402. doi:10.1007/BF02306488.
   PubMed Web of Science ®Google Scholar
• Crosson JN, Laird PW, Grossniklaus HE, Hendrick AM. Toxoplasma chorioretinitis diagnosed by histopathology in a patient with AIDS. Retin Cases Br Reports. 2015;9(2):162–163. doi:10.1097/ICB.0000000000000126.
   PubMedGoogle Scholar
• Friedman AH. The retinal lesions of the acquired immune deficiency syndrome. Trans Am Ophthalmol Soc. 1984;82(Table I):447–491. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L15102513.
   PubMedGoogle Scholar
• Hassenstein A, Meyer CH. Clinical use and research applications of Heidelberg retinal angiography and spectral‐domain optical coherence tomography–a review. Clin Exp Ophthalmol. 2009;37(1):130–143. doi:10.1111/ceo.2009.37.issue-1.
   PubMed Web of Science ®Google Scholar
• Gunturu M, Gosi SK, Kanduri S, Varicella Zoster GV. Meningitis, optic neuritis preceding the development of posterior outer retinal necrosis, and central retinal artery occlusion in a HIV patient. Case Rep Med. 2019;2019:4213162. doi:10.1155/2019/4213162.
   PubMed Web of Science ®Google Scholar
• Laovirojjanakul W, Thanathanee O. Opportunistic ocular infections in the setting of HIV. Curr Opin Ophthalmol. 2018;29(6):558–565. doi:10.1097/ICU.0000000000000531.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Chirila RM, Cowart JB. Ocular Tuberculosis. J Gen Intern Med. 2019;34(10):2288–2289. doi:10.1007/s11606-019-05129-w.
   PubMed Web of Science ®Google Scholar
• Elangovan S, Govindarajan S, Mayilvakanam L, Gunasekaran N. Clinical profile and treatment response of patients with ocular inflammation due to presumed ocular tuberculosis: a retrospective study. Turkish J Ophthalmol. 2019;49(4):188. doi:10.4274/tjo.
   PubMedGoogle Scholar
• Burke SP, Fine HF, Albini TA. Toxoplasmosis retinitis masquerading as acute retinal necrosis. Ophthalmic Surg Lasers Imaging Retina. 2016;47(10):895–899. doi:10.3928/23258160-20161004-01.
   PubMed Web of Science ®Google Scholar
• Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994;101(3):499–507. doi:10.1016/S0161-6420(13)31267-6.
   PubMed Web of Science ®Google Scholar
• Vietzke WM, Gelderman AH, Grimley PM, Valsamis MP. Toxoplasmosis complicating malignancy. Experience at the national cancer institute. Cancer. 1968;21:816–827.
   PubMed Web of Science ®Google Scholar
• Pereira-Chioccola VL, Vidal JE, Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009;4(10):1363–1379. doi:10.2217/fmb.09.89.
   PubMed Web of Science ®Google Scholar
• Benson CA, Brooks JT, Holmes KK, Kaplan JE, Masur H, Pau A Guidelines for prevention and treatment opportunistic infections in HIV-infected adults and adolescents; recommendations from CDC, the national institutes of health, and the HIV Medicine association/infectious diseases society of America. 2009.
   Google Scholar
• Mofenson LM, Brady MT, Danner SR, et al. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep. 2009;58(RR11):1–166.
   PubMedGoogle Scholar
• Gómez-Marín JE, Alvarado F, Hernández C, Cuervo S, Saravia J. Tratamiento de la fase aguda de la toxoplasmosis cerebral con Clindamicina - Falcidar (pirimetamina-sulfadoxina) en pacientes infectados por VIH. Infectio. 2001;5:163–169.
   Google Scholar
• Holland GN. Epitomes important advances in clinical medicine allergy and immunology. West J Med. 1992;157:448–449.
   PubMedGoogle Scholar
• Taqi SA, Zaki SA, Nilofer AR, Sami LB. Trimethoprim-sulfamethoxazole-induced steven johnson syndrome in an HIV-infected patient. Indian J Pharmacol. 2012;44(4):533. doi:10.4103/0253-7613.99346.
   PubMed Web of Science ®Google Scholar
• Ben-Harari RR, Goodwin E, Casoy J. Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review. Drugs R D. 2017;17(4):523–544. doi:10.1007/s40268-017-0206-8.
   PubMed Web of Science ®Google Scholar
• Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: A prospective randomized clinical trial. Int Ophthalmol. 2013;33(1):39–46. doi:10.1007/s10792-012-9634-1.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134–141. doi:10.1016/j.ophtha.2010.04.020.
   PubMed Web of Science ®Google Scholar
• Zamora YF, Arantes T, Reis FA, et al. Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone. Arq Bras Oftalmol. 2015;78(4):216–219.doi:10.5935/0004-2749.20150056.
   PubMed Web of Science ®Google Scholar
• Bahia-oliveira L, Gomez-marin J, Shapiro K Toxoplasma gondii. In: Rose JB, Jiménez-Cisneros B eds. Glob Water Pathog Proj http://www.waterpathogens.org (R Fayer W Jakubowski, Part 3 Protists) http://www.waterpathogens.org/book/toxoplasma-gondii Michigan State Univ E Lansing, MI, UNESCOgens.org/book/toxoplasma-gondii M. 2017.
   Google Scholar
• Porter SB. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med. 1992;327(23):1643–1648. doi:10.1056/NEJM199212033272306.
   PubMed Web of Science ®Google Scholar
• Richards JFO, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995;21(Supplement_1):S49–S56. doi:10.1093/clinids/21.Supplement_1.S49.
   PubMedGoogle Scholar
• Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human toxoplasmosis: a systematic review. Pathog Glob Health. 2017;111(7):333–342. doi:10.1080/20477724.2017.1370528.
   PubMed Web of Science ®Google Scholar
• Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB, Cardeal da CRL, Nascimento MA, Leite Arieta CE. Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: a three-year follow-up. Am J Ophthalmol. 2016;170:176–182. doi:10.1016/j.ajo.2016.08.003.
   PubMed Web of Science ®Google Scholar
• Borkowski PK, Brydak-Godowska J, Basiak W, Olszyńska-Krowicka M, Rabczenko D. Adverse reactions in antifolate-treated toxoplasmic retinochoroiditis. Adv Exp Med Biol. 2018;1108:37–48. doi:10.1007/5584_2018_262.
   PubMed Web of Science ®Google Scholar
• Kopec R, De CG, Chapnick E, Ghitan M, Saffra N. Prophylaxis for ocular toxoplasmosis. Clin Infect Dis. 2003;37(10):e147–e148. doi:10.1086/379125.
   PubMed Web of Science ®Google Scholar
• Silveira C, Muccioli C, Nussenblatt R, Belfort JR. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis: 10 years of follow-up. Ocular Immunology and Inflammation. 2015;23:246–247. doi:10.3109/09273948.2014.964422.
   PubMed Web of Science ®Google Scholar
• Silveira C, Belfort R, Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134(1):41–46.doi:10.1016/S0002-9394(02)01527-1.
   PubMed Web of Science ®Google Scholar
• Reich M, Becker MD, Mackensen F. 2015. Influence of drug therapy on the risk of recurrence of ocular toxoplasmosis. Br J Ophthalmol. 2016 Feb;100(2):195–199. doi:10.1136/bjophthalmol-2015-306650..
   PubMed Web of Science ®Google Scholar
• Paquet C, Yudin MH. No. 285-toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Canada. 2018;40(8):e687–e693. doi:10.1016/j.jogc.2018.05.036.
   PubMed Web of Science ®Google Scholar